Condensed Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Revenue:
Licensing fees	$ 315,092	$ 171,425
Peptide and consumer product sales	252,727	134,932
Consumer product sales to affiliated company	112,603	51,271
Total revenue	680,422	357,628
Cost of revenue:
Cost of peptide and consumer product sales	157,773	91,297
Cost of consumer product sales to affiliated company	51,758	29,530
Total cost of revenue	209,531	120,827
Gross profit	470,891	236,801
Research and development	87,085	225,163
Marketing and business development	303,106	204,437
General and administrative	384,576	341,792
Accounting, legal and professional fees	219,222	165,437
Depreciation and amortization	23,095	26,617
Total operating expenses	1,017,084	963,446
Loss from operations	(546,193)	(726,645)
Other income (expense):
Interest income	740	1,204
Amortization of debt issuance costs	(12,117)	0
Equity in earnings (loss) of affiliated company	(17,648)	7,992
Change in value of option to purchase interest in affiliated company	(6,620)	7,715
Other income (expense), net	(35,645)	16,911
Net loss and comprehensive loss	$ (581,838)	$ (709,734)
Basic and diluted net loss per share (in Dollars per share)	$ (0.01)	$ (0.01)
Weighted average shares outstanding (in Shares)	49,720,255	49,720,255